Profound Medical (NASDAQ:PROF - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Thursday, May 8th. Analysts expect Profound Medical to post earnings of ($0.29) per share and revenue of $4.78 million for the quarter.
Profound Medical (NASDAQ:PROF - Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.11. The business had revenue of $4.18 million for the quarter, compared to analyst estimates of $5.92 million. Profound Medical had a negative return on equity of 85.22% and a negative net margin of 349.41%. On average, analysts expect Profound Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Profound Medical Stock Down 4.5 %
Shares of PROF traded down $0.24 during mid-day trading on Tuesday, hitting $5.23. 20,024 shares of the company's stock were exchanged, compared to its average volume of 59,840. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.12 and a quick ratio of 5.16. Profound Medical has a 52 week low of $3.90 and a 52 week high of $11.42. The company has a market cap of $157.06 million, a PE ratio of -3.90 and a beta of 0.44. The company has a 50-day simple moving average of $5.75 and a 200 day simple moving average of $6.80.
Analyst Ratings Changes
Separately, Lake Street Capital lowered their price target on shares of Profound Medical from $17.00 to $11.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd.
Get Our Latest Stock Analysis on Profound Medical
About Profound Medical
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
Further Reading
Before you consider Profound Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Profound Medical wasn't on the list.
While Profound Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
